bevantolol

03/01/1986 - "Bevantolol administered once daily or twice daily was equally effective in the management of hypertension and was well tolerated in the doses studied."
03/01/1986 - "Two multicenter, double-blind, placebo-controlled studies were conducted to determine in patients with hypertension the oral dose of bevantolol that would effectively reduce home diastolic blood pressure to less than 95 mm Hg. The two studies differed only in once-daily or twice-daily dose administration. "
04/01/1995 - "Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. "
07/01/1993 - "These results show that bevantolol can inhibit both the hypertension and downregulation of the central beta 1-adrenoceptors induced by stress."
07/01/1987 - "Investigations in humans have shown that although bevantolol has a short half-life, good control of hypertension can be achieved on once-a-day dosing. "

11/26/1986 - "An objective assessment of the efficacy of bevantolol was performed in 21 patients with chronic, stable angina using computer-assisted exercise testing and ambulatory ST-segment monitoring. "
11/26/1986 - "Usefulness of bevantolol for chronic, stable angina pectoris."
09/01/1986 - "The efficacy and safety of bevantolol (new cardioselective beta-blocking agent without intrinsic sympathetic activity) were evaluated in chronic stable angina pectoris. "
01/01/1988 - "Available clinical data indicate that bevantolol, given once or twice daily, is an effective agent in the management of mild to moderate hypertension and stable angina pectoris. "
06/01/1988 - "A randomized, double-blind, parallel-group study design was used to compare the antianginal efficacy of bevantolol (200 to 400 mg) and atenolol (50 to 100 mg) each administrated once daily for 8 weeks in 39 patients with chronic stable angina. "

11/26/1986 - "These results suggest that bevantolol may be useful as first-line therapy in a once-daily dosage for the treatment of essential hypertension."
11/26/1986 - "The antihypertensive efficacy of bevantolol, a selective beta 1-adrenoreceptor antagonist, was evaluated in 17 patients with essential hypertension, using continuous ambulatory intraarterial blood pressure (BP) monitoring. "
06/01/1988 - "Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension."
12/01/1994 - "In patients with essential hypertension, the beta-blockers bevantolol or propranolol were administered once or twice a day for twelve weeks to evaluate the effects on blood pressure, and lipid metabolism. "
01/01/1985 - "The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo. "

12/01/2002 - "This study was designed to compare the efficacy of bevantolol, a beta(1)-selective blocker with alpha-blockade and vasodilating activity, with that of metoprolol, a beta(1)-selective receptor blocker, for the treatment of idiopathic dilated cardiomyopathy (DCM). "
12/01/2002 - "Comparison of treatment effects of bevantolol and metoprolol on cardiac function and natriuretic peptides in patients with dilated cardiomyopathy."

03/01/1986 - "Bevantolol appeared to be an effective, well-tolerated drug in the management of angina pectoris."
03/01/1986 - "The antianginal efficacy and safety of bevantolol was compared with placebo in 107 patients with angina pectoris of effort. "
01/01/1988 - "However, although the properties of bevantolol may offer theoretical advantages in some patients, only a few comparative studies have been reported, and thus it is presently unclear what advantages bevantolol may offer over existing treatments for hypertension or angina pectoris."
11/26/1986 - "Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris."
07/01/1987 - "Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. "